Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
Public ClinicalTrials.gov record NCT05607550. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of furmonertinib (firmonertinib) at 2 dose levels (160 mg once daily \[QD\] and 240 mg QD) compared to platinum-based chemotherapy in previously untreated patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations. A target of approximately 375 patients will be randomized in a 1:1:1 ratio to treatment with furmonertinib 240 mg QD, furmonertinib 160 mg QD, or platinum-based chemotherapy.
Study identification
- NCT ID
- NCT05607550
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 398 participants
Conditions and interventions
Conditions
Interventions
- furmonertinib 240 mg oral, daily Drug
- furmonertinib 160 mg oral, daily Drug
- platinum-based chemotherapy Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 1, 2023 (Actual)
- Primary completion
- Aug 15, 2025 (Estimated)
- Completion
- Feb 15, 2028 (Estimated)
- Last update posted
- Jun 22, 2025
2023 – 2028
United States locations
- U.S. sites
- 69
- U.S. states
- 28
- U.S. cities
- 67
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arrivent Investigative Site | Daphne | Alabama | 36526 | — |
| Arrivent Investigative Site | Yuma | Arizona | 85364 | — |
| Arrivent Investigative Site | Fayetteville | Arkansas | 72703 | — |
| Arrivent Investigative Site | Beverly Hills | California | 90212 | — |
| Arrivent Investigative Site | Fullerton | California | 92835 | — |
| Arrivent Investigative Site | Long Beach | California | 90806 | — |
| Arrivent Investigative Site | Los Alamitos | California | 90720 | — |
| Arrivent Investigative Site | Napa | California | 94558 | — |
| Arrivent Investigative Site | Orange | California | 90868 | — |
| Arrivent Investigative Site | Orange | California | 92868 | — |
| Arrivent Investigative site | Sacramento | California | 95817 | — |
| Arrivent Investigative Site | San Diego | California | 92123 | — |
| Arrivent Investigative Site | Santa Barbara | California | 93105 | — |
| Arrivent Investigative Site | Santa Monica | California | 90404 | — |
| Arrivent Investigative Site | Santa Rosa | California | 95403 | — |
| Arrivent Investigative Site | Whittier | California | 90602 | — |
| Arrivent Investigative Site | Hartford | Connecticut | 06102 | — |
| Arrivent Investigative Site | Norwich | Connecticut | 06360 | — |
| Arrivent Investigative Site | Fort Myers | Florida | 33901 | — |
| Arrivent Investigative Site | St. Petersburg | Florida | 33705 | — |
| Arrivent Investigative Site | The Villages | Florida | 32159 | — |
| Arrivent Investigative Site | Peoria | Illinois | 61615 | — |
| Arrivent Investigative Site | Rolling Meadows | Illinois | 60008 | — |
| Arrivent Investigative Site | Fort Wayne | Indiana | 46804 | — |
| Arrivent Investigative Site | Indianapolis | Indiana | 46250 | — |
| Arrivent Investigative Site | South Bend | Indiana | 46601 | — |
| Arrivent Investigative Site | Bethesda | Maryland | 20817 | — |
| Arrivent Investigative Site | Frederick | Maryland | 21702 | — |
| Arrivent Investigative Site | Rockville | Maryland | 20850 | — |
| Arrivent Investigative Site | Fairhaven | Massachusetts | 02719 | — |
| Arrivent Investigative Site | Lansing | Michigan | 48912 | — |
| Arrivent Investigative Site | Bolivar | Missouri | 65613 | — |
| Arrivent Investigative Site | Kansas City | Missouri | 64111 | — |
| Arrivent Investigative Site | Saint Joseph | Missouri | 64507 | — |
| Arrivent Investigative Site | St Louis | Missouri | 63110 | — |
| Arrivent Investigative Site | Omaha | Nebraska | 68114 | — |
| Arrivent Investigative Site | Belleville | New Jersey | 07109 | — |
| Arrivent Investigative Site | Englewood | New Jersey | 07631 | — |
| Arrivent Investigative Site | Florham Park | New Jersey | 07932 | — |
| Arrivent Investigative Site | The Bronx | New York | 10461 | — |
| Arrivent Investigative Site | Goldsboro | North Carolina | 27534 | — |
| ArriVent Investigative Site | Pinehurst | North Carolina | 28374 | — |
| Arrivent Investigative Site | Canton | Ohio | 44708 | — |
| Arrivent Investigative Site | Cincinnati | Ohio | 45220 | — |
| ArriVent Investigative Site | Cincinnati | Ohio | 45242 | — |
| Arrivent Investigative Site | Cleveland | Ohio | 44195 | — |
| Arrivent Investigative Site | Columbus | Ohio | 43214 | — |
| Arrivent Investigative Site | Oklahoma City | Oklahoma | 73102 | — |
| Arrivent Investigative Site | Tulsa | Oklahoma | 74146 | — |
| Arrivent Investigative Site | Salem | Oregon | 97301 | — |
| Arrivent Investigative Site | Gettysburg | Pennsylvania | 17325 | — |
| ArriVent Investigative Site | Langhorne | Pennsylvania | 19047 | — |
| Arrivent Investigative Site | York | Pennsylvania | 17403 | — |
| Arrivent Investigative Site | Greenville | South Carolina | 29607 | — |
| Arrivent Investigative Site | Sioux Falls | South Dakota | 57117 | — |
| Arrivent Investigative Site | Memphis | Tennessee | 38120 | — |
| ArriVent Investigative Site | Nashville | Tennessee | 37203 | — |
| Arrivent Investigative Site | Abilene | Texas | 79606 | — |
| ArriVent Investigative Site | Austin | Texas | 78745 | — |
| Arrivent Investigative Site | Houston | Texas | 77030 | — |
| Arrivent Investigative Site | Plano | Texas | 75093 | — |
| Arrivent Investigative Site | Ogden | Utah | 84405 | — |
| Arrivent Investigative Site | Salt Lake City | Utah | 84106 | — |
| ArriVent Investigative Site | Fairfax | Virginia | 22031 | — |
| Arrivent Investigative Site | Fredericksburg | Virginia | 22408 | — |
| Arrivent Investigative Site | Bellingham | Washington | 98225 | — |
| Arrivent Investigative Site | Spokane Valley | Washington | 99216 | — |
| Arrivent Investigative Site | Tacoma | Washington | 98405 | — |
| Arrivent Investigative Site | Appleton | Wisconsin | 54911 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 139 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05607550, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 22, 2025 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05607550 live on ClinicalTrials.gov.